To prove that CD123 is a suitable AML cell surface target for CAR-cell therapy, we investigated its differential expression on BM-derived cells either from paediatric patients at the diagnosis of AML (n = 12) or from HDs (n = 11). The gene discussed is IL3RA; the disease is acute myeloid leukemia.